1. Scrip
  2. >>Business
  3. >>Strategy

Genfit Not Fully Exiting NASH, Despite Terminating RESOLVE-IT

 
• By Joseph Haas

A fuller look at interim Phase III data shows no path forward to accelerated approval in NASH, company says. Genfit turns focus to developing elafibranor for PBC, as well as a NASH diagnostic.

businessman has to decide which direction is better
Genfit reached a tough decision to end RESOLVE-IT and focus on other business

Genfit SA said on 22 July that it is terminating the Phase III RESOLVE-IT study of elafibranor in non-alcoholic steatohepatitis following an in-depth review of interim data, first unveiled in May, which showed the PPAR alpha/delta agonist missed its primary endpoint of resolving NASH without worsening of fibrosis. The French firm also said it now will focus its business on two efforts: Phase III development of elafibranor for primary biliary cholangitis and advancement of its NIS4 biomarker test as an in vitro diagnostic for NASH treatment.

The interim top-line results from the pivotal NASH study were a major blow for Genfit, when they showed a 19.2%...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

In Brief: BioVersys And Shionogi Align In Non-Tuberculous Mycobacteria R&D

 
• By Joseph Haas

Deal Snapshot: Having recently raised an $89m IPO, BioVersys is partnering on and optioning rights to a preclinical NTM development program with Shionogi.

BerGenBio Plumps For Oncoinvent From Long List Of 50 Suitors

 
• By Kevin Grogan

The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.

Protagonist Hopes To Come From Behind In Obesity With Oral Triple Agonist

 
• By Jessica Merrill

The company announced plans to move an oral GLP-1/GIP/GCG receptor agonist peptide into clinical development for obesity in 2026.

In Brief: Sanofi Cements Support For Adagene

 
• By Kevin Grogan

Deal Snapshot: The French drugmaker has been shifting its investments away from cancer to focus on immunology and inflammation but it continues to seek out interesting early-stage oncology assets.

More from Business

In Brief: Sanofi Cements Support For Adagene

 
• By Kevin Grogan

Deal Snapshot: The French drugmaker has been shifting its investments away from cancer to focus on immunology and inflammation but it continues to seek out interesting early-stage oncology assets.

In Vivo CAR-T Interest Grows With AbbVie Acquisition

 
• By Andrew McConaghie

Acquiring Capstan gives AbbVie a stake in two competing in vivo CAR-T delivery platforms, with the field's first readouts expected in 2026.

Stock Watch: Syncona’s Wild Ride Exposes Suspect Strategies

 
• By Andy Smith

A track record of positive portfolio performance is described as an investment management skill. Taking difficult divestment decisions early, in challenging markets and outperforming benchmarks, are hallmarks of this skill. Syncona and Woodford Patient Capital offer useful case studies.